NCT03396731已完成不适用
A Prospective, Multicentre, Randomised, Assessor Blinded Study Comparing the Efficacy, Including Patient Reported Outcomes of Two Different Daily gekoTM Treatment Durations in Conjunction With Standard Care, With Each Other and to Standard Care Alone, in Patients With Venous Leg Ulcers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 171
- 试验地点
- 46
- 主要终点
- Linear healing rate (LHR)
研究概览
简要总结
Eight weeks, comprised of four weeks Run-in Phase of Standard Care (SC) treatment followed by four weeks of treatment allocated by randomisation (Treatment Phase).
To compare two daily geko™ device treatment durations, six hours and 12 hours, in conjunction with SC, with each other and to SC alone, in patients with venous leg ulcers
详细描述
- Screen patient database to identify eligible patients
- Obtain informed consent and inform participant's GP
- Complete CRF throughout the study period (demographics, vital signs, medical history, study ulcer history, concomitant medication)
- Physical examination at the study start up visit and at consecutive weekly visits
- Take a digital image of the wound at participants weekly visits
- Assess and report adverse events
- Apply standard care (compression bandaging) at weekly visits and record all the dressing usage
- Perform randomisation at the end of week 4 and allocate participant to one of the three treatment groups.
- Train the participant to use gekoTM devices
- Schedule weekly visits
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
The assessors will be blinded to the study participants and what treatment they are receiving.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Potential subjects are required to meet all of the following criteria for enrollment into the study and subsequent randomization.
- •Male or female aged ≥ 18 years and able to provide written informed consent.
- •Intact healthy skin at the site of gekoTM device application.
- •Patients who have a chronic venous leg ulcer determined to be due to underlying venous disease following evaluation in a multidisciplinary clinic setting.
- •A VLU of approximately ≥ 3cm2 and ≤ 39 cm2 at study enrolment i.e. Run In Phase Visit 1 (RV1). The largest ulcer within the given size range will be designated the study ulcer and the only one included in the study. If other ulcerations are present on the same leg they have to be more than 2 cm apart if they are separate wounds.
- •Study ulcer (current episode of ulceration in case of ulcer recurrence) has been present for at least 6 weeks but no more than 5 years prior to study entry (i.e. RV1).
- •Ankle-Brachial Pressure Index (ABPI) of 0.75-1.24 inclusive measured at study entry or within 8 weeks prior to study entry (i.e. RV1).
- •No active local or systemic infection for a minimum of 48 hours prior to study entry (i.e. RV1).
- •No systemic antimicrobial treatment for a minimum of seven days prior to study entry prescribed for index wound infection (i.e. RV1).
- •Patient understands and is willing to participate in the study and is able to comply with study procedures and visits.
- •Note: At the randomisation visit, the study ulcer needs to be ≥ 2 cm2 and ≤ 30 cm2.
排除标准
- •Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent randomisation:
- •Known allergy to any of the protocol-stipulated treatments, or non-tolerance of multilayer, multicomponent compression therapy.
- •History of significant haematological disorders (e.g. Sickle Cell disease).
- •History of Deep Vein Thrombosis (DVT) within six months preceding study entry (i.e. RV1).
- •History of Pyoderma Gangrenosum or other inflammatory ulceration.
- •Pregnancy or breast feeding.
- •Use of investigational drug or device within four weeks prior to study entry (i.e. RV1) that may interfere with this study.
- •Use of any neuro-modulation device.
- •Surgery during three months prior to study entry (such as abdominal, gynaecological, hip or knee replacement) (i.e. RV1).
- •Trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve.
- •No involuntary movement of the lower leg/foot at the maximum tolerable device setting.
- •Any medication deemed by the Investigator to potentially interfere with the study treatment (e.g. systemic steroids).
- •Participation in any other clinical study.
结局指标
主要结局
Linear healing rate (LHR)
时间窗: 8 weeks
Linear healing rate will be studied on a weekly basis
次要结局
- Wound healing rate(Upto 8 weeks)
- Pain reduction(Upto 8 weeks)
- Change in Quality of Life(Upto 8 weeks)
研究者
研究点 (46)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to test whether taking BI 1358894 for 8 weeks helps adults with post-traumatic stress disorderPost-Traumatic Stress Disorder (PTSD)MedDRA version: 21.1Level: PTClassification code 10036316Term: Post-traumatic stress disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2021-003154-23-SEBoehringer Ingelheim AB286
进行中（未招募）
1 期
A study to test whether taking BI 1358894 for 8 weeks helps adults with post-traumatic stress disorderEUCTR2021-003154-23-HRBoehringer Ingelheim RCV GmbH & Co KG286
进行中（未招募）
1 期
A study to test whether taking BI 1358894 for 8 weeks helps adults with post-traumatic stress disorderPost-Traumatic Stress Disorder (PTSD)MedDRA version: 21.1Level: PTClassification code 10036316Term: Post-traumatic stress disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2021-003154-23-PL286
进行中（未招募）
1 期
A study to test whether taking BI 1358894 for 8 weeks helps adults with post-traumatic stress disorderPost-Traumatic Stress Disorder (PTSD)MedDRA version: 21.1Level: PTClassification code 10036316Term: Post-traumatic stress disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2021-003154-23-FIBoehringer-Ingelheim B.V.286
进行中（未招募）
1 期
A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacerbation of schizophrenia. - CandlelyteEUCTR2010-021984-33-SKF. Hoffmann-La Roche Ltd380